Alhadi advises the Steward team across key business initiatives and areas opportune for deployment of the firm’s strategy. He has been a strong source of emerging firms for the Steward pipeline. Currently, he is a Partner at Bio-nAbler, a life-science investment and advisory firm. He has spent the last twenty years focused on alternative investments in private equity with a focus on life sciences, infrastructure and real estate.

Alhadi is a member of the board of directors of Celon Laboratories Limited, an oncology and critical care drug manufacturer that focuses on novel drug delivery systems and is an advisor to the Board of Directors of Mango Sciences, a big data, advanced computational data platform that enables novel drug companies to access a larger pool of patients by providing outcomes-based costing solutions for life-saving therapeutics.

Prior to Bio-nAbler, Alhadi was a Partner in Eastgate Capital Group’s private equity and real estate practice, where he led initiatives in healthcare, infrastructure and real estate. Prior to the formation of Eastgate, Alhadi worked at NCB’s Capital Markets Group, where he was responsible for reviewing, negotiating and structuring select private equity investments. Before joining NCB, Alhadi was SVP and Director at Iron Gate Partners, a private investment group with offices in Washington and London, where he managed investments in private equity, fixed income securities, structured credit products and real estate.  Previously, Alhadi was a Financial Engineer at Société Générale with the Derivative and Financial Products Group in New York City. He began his career at STX Hughes working on the Solar Maximum Mission Project at NASA’s Goddard Space Flight Centre.

Alhadi holds a B.Sc. degree (Summa Cum Laude) in Aerospace Engineering from the University of Maryland and an M.B.A. from Georgetown University, McDonough School of Business.